-
公开(公告)号：US10745364B2
公开(公告)日：2020-08-18
申请号：US16270882
申请日：2019-02-08
Applicant: Merck Sharp & Dohme Corp. , Lycera Corporation
Inventor： Thomas D. Aicher , Chad A. VanHuis , William D. Thomas , John K. MacLean , Brian M. Andresen , Kenneth J. Barr , Corey E. Bienstock , Neville J. Anthony , Matthew Daniels , Kun Liu , Yuan Liu , Catherine M. White , Blair T. Lapointe , Nunzio Sciammetta , Vladimir Simov
IPC: C07D265/36 , C07D413/14 , C07D215/58 , C07D401/06 , C07D401/12 , C07D413/04 , C07D471/04 , A61K31/4375 , A61K31/47 , A61K31/4709 , A61K31/538 , A61K45/06 , C07D413/06 , C07D413/12 , C07D417/06 , C07D487/04
Abstract: The invention provides certain bicylic heterocyclic compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein X1, X2, R1, R2, R3, R4, and Cy are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds of the Formula (I) or pharmaceutically acceptable salts thereof, and methods of using the compounds of the Formula (I) or pharmaceutically acceptable salts thereof or pharmaceutical compositions comprising the same for treating diseases or conditions mediated by RORgammaT.
-
2.发明申请2-ACYLAMIDOMETHYL AND SULFONYLAMIDOMETHYL BENZOXAZINE CARBAMATES FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE 有权2-氨基甲酰乙酰和亚磺酰氨基苯甲酰胺碳酸酯抑制罗尔玛活性和治疗疾病公开(公告)号：US20160304505A1
公开(公告)日：2016-10-20
申请号：US15103407
申请日：2014-12-19
Applicant: MERCK SHARP & DOHME CORP. , LYCERA CORPORATION
Inventor： Thomas D. Aicher , Chad A. VanHuis , John MacLean , Brian M. Andresen , Kenneth J. Barr , Corey Bienstock , Neville J. Anthony , Matthew Daniels , Yuan Liu , Catherine White , Blair T. Lapointe , Nunzio Sciammetta , Vladimir Simov , Wesley B. Trotter , Kun Liu
IPC: C07D413/12 , A61K31/538 , C07D265/36 , C07D413/14 , C07D498/04 , C07D513/04 , C07D487/04 , C07D417/12 , A61K45/06 , C07D471/04
CPC classification number: C07D413/12 , A61K31/538 , A61K45/06 , C07D265/36 , C07D413/14 , C07D417/12 , C07D471/04 , C07D487/04 , C07D498/04 , C07D513/04
Abstract: The invention provides certain benzoxazine compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, Ra, Rb, Rc, Rd, Rg, and Cy are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds of the Formula (I) or pharmaceutically acceptable salts thereof, and methods of using the compounds of the Formula (I) or pharmaceutically acceptable salts thereof or pharmaceutical compositions comprising the same for treating diseases or conditions mediated by RORgammaT.
-
公开(公告)号：US20190292159A1
公开(公告)日：2019-09-26
申请号：US16270882
申请日：2019-02-08
Applicant: Merck Sharp & Dohme Corp. , Lycera Corporation
Inventor： Thomas D. Aicher , Chad A. VanHuis , William D. Thomas , John K. MacLean , Brian M. Andresen , Kenneth J. Barr , Corey E. Bienstock , Neville J. Anthony , Matthew Daniels , Kun Liu , Yuan Liu , Catherine M. White , Blair T. Lapointe , Nunzio Sciammetta , Vladimir Simov
IPC: C07D265/36 , C07D413/12 , A61K31/4709 , C07D413/06 , C07D487/04 , C07D417/06 , C07D471/04 , C07D413/04 , C07D401/12 , C07D401/06 , C07D215/58 , C07D413/14 , A61K45/06 , A61K31/538 , A61K31/4375 , A61K31/47
Abstract: The invention provides certain bicylic heterocyclic compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein X1, X2, R1, R2, R3, R4, and Cy are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds of the Formula (I) or pharmaceutically acceptable salts thereof, and methods of using the compounds of the Formula (I) or pharmaceutically acceptable salts thereof or pharmaceutical compositions comprising the same for treating diseases or conditions mediated by RORgammaT.
-
公开(公告)号：US10221146B2
公开(公告)日：2019-03-05
申请号：US15730997
申请日：2017-10-12
Applicant: Merck Sharp & Dohme Corp. , Lycera Corporation
Inventor： Thomas D. Aicher , Chad A. VanHuis , William D. Thomas , John K. MacLean , Brian M. Andresen , Kenneth J. Barr , Corey E. Bienstock , Neville J. Anthony , Matthew Daniels , Kun Liu , Yuan Liu , Catherine M. White , Blair T. Lapointe , Nunzio Sciammetta , Vladimir Simov
IPC: C07D265/36 , C07D413/14 , C07D215/58 , C07D401/06 , C07D401/12 , C07D413/04 , C07D471/04 , A61K31/4375 , A61K31/47 , A61K31/4709 , A61K31/538 , A61K45/06 , C07D413/06 , C07D413/12 , C07D417/06 , C07D487/04
Abstract: The invention provides certain bicyclic heterocyclic compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein X1, X2, R1, R2, R3, R4, and Cy are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds of the Formula (I) or pharmaceutically acceptable salts thereof, and methods of using the compounds of the Formula (I) or pharmaceutically acceptable salts thereof or pharmaceutical compositions comprising the same for treating diseases or conditions mediated by RORgammaT.
-
公开(公告)号：US09809561B2
公开(公告)日：2017-11-07
申请号：US15103414
申请日：2014-12-19
Applicant: Merck Sharp & Dohme Corp. , Lycera Corporation
Inventor： Thomas D. Aicher , Chad A. VanHuis , William D. Thomas , John K. MacLean , Brian M. Andresen , Kenneth J. Barr , Corey E. Bienstock , Neville J. Anthony , Matthew Daniels , Kun Liu , Yuan Liu , Catherine M. White , Blair T. Lapointe , Nunzio Sciammetta , Vladimir Simov
IPC: C07D265/36 , C07D413/14 , C07D215/58 , C07D401/06 , C07D401/12 , C07D413/04 , C07D471/04 , A61K31/4375 , A61K31/47 , A61K31/4709 , A61K31/538 , A61K45/06 , C07D413/06 , C07D413/12 , C07D417/06 , C07D487/04
CPC classification number: C07D265/36 , A61K31/4375 , A61K31/47 , A61K31/4709 , A61K31/538 , A61K45/06 , C07D215/58 , C07D401/06 , C07D401/12 , C07D413/04 , C07D413/06 , C07D413/12 , C07D413/14 , C07D417/06 , C07D471/04 , C07D487/04
Abstract: The invention provides certain bicylic heterocyclic compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein X1, X2, R1, R2, R3, R4, and Cy are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds of the Formula (I) or pharmaceutically acceptable salts thereof, and methods of using the compounds of the Formula (I) or pharmaceutically acceptable salts thereof or pharmaceutical compositions comprising the same for treating diseases or conditions mediated by RORgammaT.
-
Patent Agency Ranking
6.发明申请CARBAMATE BENZOXAZINE PROPIONIC ACIDS AND ACID DERIVATIVES FOR MODULATION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE 有权用于调节罗丹明活性和疾病治疗的碳酸酯苯并咪唑酸和酸衍生物公开(公告)号：US20160311787A1
公开(公告)日：2016-10-27
申请号：US15103409
申请日：2014-12-19
Applicant: MERCK SHARP & DOHME CORP. , LYCERA CORPORATION
Inventor： Thomas D. Aicher , Chad A. VanHuis , John MacLean , Brian M. Andresen , Kenneth J. Barr , Corey Bienstock , Matthew Daniels , Kun Liu , Yuan Liu , Catherine White , Nunzio Sciammetta , Vladimir Simov
IPC: C07D265/36 , C07D413/12 , C07D417/12 , C07D471/04 , C07D513/04 , A61K31/538 , C07D487/04
CPC classification number: C07D265/36 , A61K31/538 , C07D413/12 , C07D417/12 , C07D471/04 , C07D487/04 , C07D513/04
Abstract: The invention provides certain benzoxazine compounds of the Formula (I) or pharmaceutically acceptable salts thereof wherein R1, R2, Ra1, Ra2, Rb1, Rb2, Rc, Rd, and Cy are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds of the Formula (I) or pharmaceutically acceptable salts thereof, and methods of using the compounds of the Formula (I) or pharmaceutically acceptable salts thereof or pharmaceutical compositions comprising the same for treating diseases or conditions mediated by RORgammaT.
-
公开(公告)号：US20180030005A1
公开(公告)日：2018-02-01
申请号：US15730997
申请日：2017-10-12
Applicant: Merck Sharp & Dohme Corp. , Lycera Corporation
Inventor： Thomas D. Aicher , Chad A. VanHuis , William D. Thomas , John K. MacLean , Brian M. Andresen , Kenneth J. Barr , Corey E. Bienstock , Neville J. Anthony , Matthew Daniels , Kun Liu , Yuan Liu , Catherine M. White , Blair T. Lapointe , Nunzio Sciammetta , Vladimir Simov
IPC: C07D265/36 , A61K31/4375 , C07D417/06 , C07D413/14 , C07D413/12 , C07D413/06 , C07D413/04 , C07D401/12 , C07D401/06 , C07D215/58 , A61K45/06 , A61K31/538 , A61K31/4709 , A61K31/47 , C07D471/04 , C07D487/04
CPC classification number: C07D265/36 , A61K31/4375 , A61K31/47 , A61K31/4709 , A61K31/538 , A61K45/06 , C07D215/58 , C07D401/06 , C07D401/12 , C07D413/04 , C07D413/06 , C07D413/12 , C07D413/14 , C07D417/06 , C07D471/04 , C07D487/04 , Y02A50/409
Abstract: The invention provides certain bicylic heterocyclic compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein X1, X2, R1, R2, R3, R4, and Cy are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds of the Formula (I) or pharmaceutically acceptable salts thereof, and methods of using the compounds of the Formula (I) or pharmaceutically acceptable salts thereof or pharmaceutical compositions comprising the same for treating diseases or conditions mediated by RORgammaT.
-
公开(公告)号：US09783511B2
公开(公告)日：2017-10-10
申请号：US15103409
申请日：2014-12-19
Applicant: Merck Sharp & Dohme Corp. , Lycera Corporation
Inventor： Thomas D. Aicher , Chad A. VanHuis , John MacLean , Brian M. Andresen , Kenneth J. Barr , Corey Bienstock , Matthew Daniels , Kun Liu , Yuan Liu , Catherine White , Nunzio Sciammetta , Vladimir Simov
IPC: C07D265/36 , A61K31/538 , C07D413/12 , C07D513/04 , C07D417/12 , C07D471/04 , C07D487/04
CPC classification number: C07D265/36 , A61K31/538 , C07D413/12 , C07D417/12 , C07D471/04 , C07D487/04 , C07D513/04
Abstract: The invention provides certain benzoxazine compounds of the Formula (I) or pharmaceutically acceptable salts thereof wherein R1, R2, Ra1, Ra2, Rb1, Rb2, Rc, Rd, and Cy are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds of the Formula (I) or pharmaceutically acceptable salts thereof, and methods of using the compounds of the Formula (I) or pharmaceutically acceptable salts thereof or pharmaceutical compositions comprising the same for treating diseases or conditions mediated by RORgammaT.
-
公开(公告)号：US09663502B2
公开(公告)日：2017-05-30
申请号：US15103407
申请日：2014-12-19
Applicant: Merck Sharp & Dohme Corp. , Lycera Corporation
Inventor： Thomas D. Aicher , Chad A. VanHuis , John MacLean , Brian M. Andresen , Kenneth J. Barr , Corey Bienstock , Neville J. Anthony , Matthew Daniels , Yuan Liu , Catherine White , Blair T. Lapointe , Nunzio Sciammetta , Vladimir Simov , Wesley B. Trotter , Kun Liu
IPC: C07D265/36 , C07D413/12 , C07D471/04 , A61K31/538 , A61K45/06 , C07D413/14 , C07D417/12 , C07D487/04 , C07D498/04 , C07D513/04
CPC classification number: C07D413/12 , A61K31/538 , A61K45/06 , C07D265/36 , C07D413/14 , C07D417/12 , C07D471/04 , C07D487/04 , C07D498/04 , C07D513/04
Abstract: The invention provides certain benzoxazine compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, Ra, Rb, Rc, Rd, Rg, and Cy are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds of the Formula (I) or pharmaceutically acceptable salts thereof, and methods of using the compounds of the Formula (I) or pharmaceutically acceptable salts thereof or pharmaceutical compositions comprising the same for treating diseases or conditions mediated by RORgammaT.
-
10.发明申请TETRAHYDRONAPHTHYRIDINE, BENZOXAZINE, AZA-BENZOXAZINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE 有权四氢萘啶，苯并吖嗪，AZA-BENZOXAZINE和相关双酚化合物用于抑制RORGAMMA活性和治疗疾病公开(公告)号：US20160304476A1
公开(公告)日：2016-10-20
申请号：US15103414
申请日：2014-12-19
Applicant: MERCK SHARP & DOHME CORP. , LYCERA CORPORATION
Inventor： Thomas D. Aicher , Chad A. VanHuis , William D. Thomas , John K. MacLean , Brian M. Andresen , Kenneth J. Barr , Corey E. Bienstock , Neville J. Anthony , Matthew Daniels , Kun Liu , Yuan Liu , Catherine M. White , Blair T. Lapointe , Nunzio Sciammetta , Vladimir Simov
IPC: C07D265/36 , A61K31/538 , C07D413/12 , C07D417/06 , C07D413/06 , C07D413/14 , C07D471/04 , A61K31/4375 , C07D215/58 , C07D401/12 , C07D413/04 , C07D487/04 , A61K31/47 , A61K31/4709 , A61K45/06
CPC classification number: C07D265/36 , A61K31/4375 , A61K31/47 , A61K31/4709 , A61K31/538 , A61K45/06 , C07D215/58 , C07D401/06 , C07D401/12 , C07D413/04 , C07D413/06 , C07D413/12 , C07D413/14 , C07D417/06 , C07D471/04 , C07D487/04
Abstract: The invention provides certain bicylic heterocyclic compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein X1, X2, R1, R2, R3, R4, and Cy are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds of the Formula (I) or pharmaceutically acceptable salts thereof, and methods of using the compounds of the Formula (I) or pharmaceutically acceptable salts thereof or pharmaceutical compositions comprising the same for treating diseases or conditions mediated by RORgammaT.
-
-
-
-
-
-
-
-
-
Search Results
12
records
(took 0.044 seconds)
